Holen Sie sich die Stockscreener-App
8.09
2.53%
-0.21
Handel nachbörslich:
8.09
Schlusskurs vom Vortag:
$8.30
Offen:
$8.24
24-Stunden-Volumen:
147.03K
Relative Volume:
0.43
Marktkapitalisierung:
$688.68M
Einnahmen:
$81.18M
Nettoeinkommen (Verlust:
$-80.94M
KGV:
-6.8507
EPS:
-1.1809
Netto-Cashflow:
$-55.15M
1W Leistung:
-0.61%
1M Leistung:
+18.27%
6M Leistung:
+91.48%
1J Leistung:
+137.24%
1-Tages-Spanne:
$8.0625
$8.30
1-Wochen-Bereich:
$7.82
$8.62
52-Wochen-Spanne:
$3.10
$8.98
Sophia Genetics Sa Stock (SOPH) Company Profile
Firmenname
Sophia Genetics Sa
Sektor
Branche
Telefon
-
Adresse
-
Compare SOPH vs VEEV, BTSG, TEM, TXG, HQY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SOPH
Sophia Genetics Sa
|
8.09 | 709.11M | 81.18M | -80.94M | -55.15M | -1.1809 |
VEEV
Veeva Systems Inc
|
275.09 | 40.70B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
60.73 | 11.78B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
64.62 | 12.03B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
62.65 | 8.32B | 638.78M | -22.66M | 122.18M | -0.1744 |
HQY
Healthequity Inc
|
96.07 | 8.72B | 1.34B | 230.70M | 440.96M | 2.6695 |
Sophia Genetics Sa Stock (SOPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Craig Hallum | Buy |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | Guggenheim | Buy |
| 2023-11-29 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-03 | Eingeleitet | BTIG Research | Buy |
| 2022-11-23 | Eingeleitet | Credit Suisse | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-17 | Eingeleitet | Cowen | Outperform |
| 2021-08-17 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-08-17 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Sophia Genetics Sa Aktie (SOPH) Neueste Nachrichten
SOPHiA GENETICS Chief Scientific Officer Xu Zhenyu Sells 20,000 Shares Over Three Days - Kalkine Media
SOPHiA GENETICS (NASDAQ: SOPH) officer may sell founder shares - Stock Titan
SOPHiA GENETICS (NASDAQ: SOPH) officer lines up 10,000-share sale - Stock Titan
SOPHiA GENETICS (NASDAQ: SOPH) officer plans additional 8,000-share sale - Stock Titan
SOPHiA GENETICS (NASDAQ:SOPH) Hits New 12-Month HighShould You Buy? - MarketBeat
EBIT per share of SOPHiA GENETICS SA – DUS:90B - TradingView
SOPHiA GENETICS SA (NASDAQ:SOPH) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
SOPHiA Genetics Earnings Call Highlights Growth Push - TipRanks
SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript - AOL.com
Sophia Genetics SA (SOPH) Chief Scientific Officer Zhenyu Xu Sel - GuruFocus
SOPHiA GENETICS (SOPH) Slips 1.57% as Shares Consolidate Between Key Support and ResistanceStock Surge Alerts - vinanet.vn
SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 5,000 Shares - MarketBeat
Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells 4,000 Shares of Stock - MarketBeat
SOPHiA GENETICS (SOPH) Slips 0.53% to $7.57 as Genomics AI Stock Consolidates Between Key LevelsSeasonality Effect - Vinanet
SOPHiA GENETICS (SOPH) Consolidates at $7.57: Genomics Stock Poised Between Support and ResistanceCorrective Wave - vinanet.vn
Sophia Genetics (SOPH) Executive Chairman Jurgi Camblong Sells 2 - GuruFocus
SOPHiA GENETICS (NASDAQ:SOPH) Reaches New 52-Week HighTime to Buy? - MarketBeat
Jurgi Camblong Sells 8,500 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock - MarketBeat
Abhimanyu Verma Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock - MarketBeat
SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells 20,000 Shares - MarketBeat
Sei Investments Co. Buys Shares of 357,888 SOPHiA GENETICS SA $SOPH - MarketBeat
SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $123,930.00 in Stock - MarketBeat
SOPH (NASDAQ: SOPH) insider schedules 22,000-share sale under 10b5-1 plan - Stock Titan
SOPHiA GENETICS (SOPH) insider plans Rule 144 sale after 10b5-1 trades - Stock Titan
Sophia Genetics CSO Zhenyu Xu disposes of USD 170,872 in common shares - Bitget
SOPHiA GENETICS Q3 EPS Estimate Lowered by HC Wainwright - MarketBeat
Three Swiss biotechs widen their reach into pharma, paediatrics and lung disease - Startupticker.ch
HC Wainwright Predicts Reduced Earnings for SOPHiA GENETICS - MarketBeat
SOPHiA GENETICS (NASDAQ:SOPH) Insider Zhenyu Xu Sells 10,000 Shares - MarketBeat
SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells $138,400.00 in Stock - MarketBeat
BTIG raises Sophia Genetics stock price target on CDx deals By Investing.com - Investing.com South Africa
SOPHiA GENETICS (NASDAQ:SOPH) Hits New 52-Week High After Analyst Upgrade - MarketBeat
SOPH Stock Price and Chart — NASDAQ:SOPH - tradingview.com
BTIG Research Issues Positive Forecast for SOPHiA GENETICS (NASDAQ:SOPH) Stock Price - MarketBeat
SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
SOPHiA GENETICS Updates Investors With Q2 2026 Form 6-K Filing - The Globe and Mail
BTIG raises Sophia Genetics stock price target on CDx deals - Investing.com
SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics - Yahoo Finance
SOPHiA GENETICS (NASDAQ:SOPH) Shares Up 10.5%Here's Why - MarketBeat
Jurgi Camblong (SOPH) plans 20,000-share sale and details 10b5-1 trades - Stock Titan
SOPHiA GENETICS (SOPH) insider Zhenyu Xu plans 10,000-share stock sale - Stock Titan
Sophia Genetics SA (SOPH) (Q2 2026) Earnings Call Highlights: Record Revenue Growth and ... - Yahoo! Finance Canada
SOPHiA GENETICS Q2 Earnings Call Highlights - MarketBeat
Sophia Genetics SA and AstraZeneca Enter Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies - marketscreener.com
SOPH: Q2 revenue up 27% year-over-year, guidance raised, and major biopharma wins secured - TradingView
Earnings call transcript: SOPHiA GENETICS tops revenue estimates in Q2 2026 - Investing.com
SOPH Looks 11.8% Overvalued on GF Value™ - GuruFocus
SOPHiA GENETICS (NASDAQ:SOPH) Issues Quarterly Earnings Results - MarketBeat
Sophia Genetics SA reports results for the quarter ended June 30Earnings Summary - TradingView
SOPH: Q2 2026 revenue rose 27% YoY, with strong U.S. and Liquid Biopsy growth and improved EBITDA loss - TradingView
[6-K] SOPHiA GENETICS SA Current Report (Foreign Issuer) - Stock Titan
Finanzdaten der Sophia Genetics Sa-Aktie (SOPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sophia Genetics Sa-Aktie (SOPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Menu Philippe | Chief Medical Officer |
Aug 25 '26 |
Sale |
8.68 |
5,000 |
43,396 |
213,387 |
| HIBBS KATHY L | Director |
Aug 25 '26 |
Sale |
8.68 |
6,250 |
54,233 |
103,242 |
| Verma Abhimanyu | Chief Technology Officer |
Aug 24 '26 |
Sale |
8.80 |
5,000 |
44,000 |
172,171 |
| Verma Abhimanyu | Chief Technology Officer |
Aug 19 '26 |
Sale |
8.20 |
5,000 |
41,000 |
177,171 |
0.03%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):